News
4d
News-Medical.Net on MSNWhich GLP-1 meds have the most side effects? Study of 60,000 Facebook posts gives answersResearchers analyzed nearly 60,000 public Facebook posts to identify real-world adverse events linked to GLP-1 receptor ...
Weight-loss drugs like semaglutide and tirzepatide may help shrink waistlines, but new research shows they fail to boost ...
While many believe the agents to be potential game changers, evidence is still lacking in psoriatic disease, and experts urge ...
Detailed price information for Lexaria Bioscience Corp WT (LEXXW-Q) from The Globe and Mail including charting and trades.
The U.S. Food & Drug Administration (FDA) has approved certain GLP-1 drugs for commercialization and use, including liraglutide ...
DehydraTECH-semaglutide reduces overall side effects by 36.5% as compared to Rybelsus®DehydraTECH-semaglutide reduces gastrointestinal side effects by 43.5% as compared to Rybelsus®DehydraTECH-GLP-1 s ...
GLP-1 receptor agonists are an important drug class and have become widely popular due to their effectiveness in weight ...
16d
Best Life on MSNDoctors Discover the GLP-1 Drug Combo That Supercharges Weight Loss After MenopauseCombing a weight-loss drug and hormone therapy may be the key to shedding pounds.
17d
News-Medical.Net on MSNEffective weight loss achieved even with inconsistent GLP-1 accessPopular anti-obesity medications continue to be effective for weight loss even when availability and access is interrupted, according to a study being presented by a private weight-loss company Monday ...
18d
HealthDay on MSNMenopause Hormone Therapy Boosts GLP-1 Drug Effectiveness, Researchers SayKey Takeaways Menopause hormone therapy appears to boost the effectiveness of tirzepatide (Zepbound)Women lost more weight with the combo, and more women lost at least 20% of body weightThe findings ...
19d
MedPage Today on MSNGLP-1 Therapy Helps Amplify Bariatric Surgery Weight Loss, But Timing MattersIn 568 patients who underwent bariatric surgery, those who also used a GLP-1 receptor agonist during the preoperative and postoperative period experienced significantly greater weight loss -- a 33% ...
“Patients taking GLP-1 treatments like semaglutide and tirzepatide often face challenges consistently accessing their medications due to supply shortages or insurance coverage obstacles,” said ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results